Мултисистемен инфламаторен синдром след КОВИД-19 в детска възраст и генетична предразположеност

  • Маргарита Ганева
Keywords: мултисистемен инфламаторен синдром, детска възраст, генетични фактори

Abstract

Мултисистемният инфламаторен синдром при деца (MIS-C) се наблюдава 3-6 седмици след КОВИД-19. Клиничната симптоматика на MIS-C включва фебрилитет, обрив, конюнктивит, гастроинтестинална или друга органна симптоматика, включително сърдечна дисфункция. Честотата на MIS-C е 2 / 100 000 деца със SARS-CoV-2.

Интерес представлява въпросът защо MIS-C не се наблюдава при всички деца след КОВИД-19. До този момент няколко кандидат гена, свързани с развитието на MIS-C, са предложени като предразполагащи. Малкият брой предложени гени е свързан вероятно и с относително малкия размер на кохортите деца с MIS-C. Все още не са налични голям брой проучвания, свързани с генетичната предразположеност при това състояние. В настоящия обзор се разглеждат публикуваните до момента.

References

World Health Organization. Director General's remarks at the media briefing on 2019-nCoV on 11 February 2020. http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020.
Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet. 2020 May 23;395(10237):1607-1608.
Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet. 2020 Jun 6;395(10239):1771-1778.
Health Policy Team. Royal College of Paediatrics and Child Health; London, UK: [(accessed on 29 July 2020)]. Guidance—Paediatric Multisystem Inflammatory Syndrome Temporally Associated with COVID-19. Available online: https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19
Centers for Disease Control and Prevention (CDC) CDC; Atlanta, GA, USA: [(accessed on 29 July 2020)]. Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C) Available online: https://www.cdc.gov/mis-c/hcp/
World Health Organization (WHO) WHO; Geneva, Switzerland: May 15, 2020. [(accessed on 29 July 2020)]. Multisystem Inflammatory Syndrome in Children and Adolescents Temporally Related to COVID-19. Available online: https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19
Dufort EM, Koumans EH, Chow EJ, et al. Multisystem Inflammatory Syndrome in Children in New York State. N Engl J Med. 2020 Jul 23;383(4):347-358.
Noval Rivas M, Porritt RA, Cheng MH, et al. COVID-19-associated multisystem inflammatory syndrome in children (MIS-C): a novel disease that mimics toxic shock syndrome-the superantigen hypothesis. J Allergy Clin Immunol 2021; 147(1):57–9.
Vella LA, Giles JR, Baxter AE, et al. Deep immune profiling of MIS-C demonstrates marked but transient immune activation compared to adult and pediatric COVID-19. Sci Immunol 2021;6(57). eabf7570.47.
Rostad CA, Chahroudi A, Mantus G, et al. Quantitative SARS-CoV-2 serology in children with multisystem inflammatory syndrome (MIS-C). Pediatrics 2020; 146(6).
Pang J, Boshier FAT, Alders N, et al. SARS-CoV-2 Polymorphisms and Multisystem Inflammatory Syndrome in Children. Pediatrics. 2020 Dec;146(6):e2020019844.
Lee PY, Platt CD, Weeks S, et al. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. J Allergy Clin Immunol. 2020 Nov;146(5):1194-1200.e1.
Liau NPD, Laktyushin A, Lucet IS, et al. The molecular basis of JAK/STAT inhibition by SOCS1. Nat Commun. 2018 Apr 19;9(1):1558.
Chou J, Platt CD, Habiballah S, et al. Taking on COVID-19 Together Study Investigators. Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C). J Allergy Clin Immunol. 2021 Sep;148(3):732-738.e1.
Marsh RA, Madden L, Kitchen BJ, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 2010;116:1079-82.
Yabal M, Muller N, Adler H, et al. XIAP Restricts TNF- and RIP3-dependent cell death and inflammasome activation. Cell Rep 2014;7:1796-808.
Abolhassani H, Landegren N, Bastard P, et al. Inherited IFNAR1 Deficiency in a child with both critical COVID-19 Pneumonia and Multisystem Inflammatory Syndrome. J Clin Immunol. 2022;42:471–83.
Vagrecha A, Zhang M, Acharya S, et al. Hemophagocytic Lymphohistiocytosis Gene Variants in Multisystem Inflammatory Syndrome in Children. Biology (Basel). 2022 Mar 9;11(3):417.
Abuhammour W, Yavuz L, Jain R, et al. Genetic and Clinical Characteristics of Patients in the Middle East With Multisystem Inflammatory Syndrome in Children. JAMA Netw Open. 2022 May 2;5(5):e2214985.
Published
2022-08-03
How to Cite
1.
Ганева М. Мултисистемен инфламаторен синдром след КОВИД-19 в детска възраст и генетична предразположеност. Редки болести и лекарства сираци [Internet]. 2022Aug.3 [cited 2022Aug.17];13(2):22-5. Available from: https://journal.raredis.org/index.php/RBLS/article/view/163
Section
Статии